Double Digit Stock Gainers with News: SLXN, SYTA, TRIB, and BACK

January 28, 2025

DENVER, Colo., Jan 28, 2025 (247marketnews.com)- Silexion Therapeutics (NASDAQ: SLXN) is today’s most active double-digit gainer with news. Silexion unveiled promising new preclinical data for its next-generation siRNA therapeutic candidate, SIL-204. The findings highlight the potential of systemic administration as an effective delivery approach, showcasing significant tumor growth reduction in orthotopic pancreatic cancer models—a platform designed to closely mimic human cancer progression.

With these encouraging results, Silexion is one step closer to advancing SIL-204 into clinical development, with the potential to offer a transformative therapy for patients battling KRAS-driven cancers.

Siyata Mobile (NASDAQ: SYTA), a leading provider of Push-to-Talk over Cellular (PoC) devices and cellular signal booster systems, secured a significant order for several thousand SD7 handsets and related accessories from a major transit authority in the western United States. This new customer serves tens of millions of passengers annually and is making the transition from outdated radio-based communication systems to Siyata’s advanced PoC technology.

Marc Seelenfreund, Siyata’s CEO, commented, “This new order underscores our continued sales momentum in the transit and public works sectors across the U.S. This customer, which serves tens of millions of passengers annually, is transitioning from outdated radio-based communication systems to Push-to-Talk over Cellular with our SD7 handsets and accessories. This shift will not only modernize its communications infrastructure but also provide seamless, reliable communication for employees who are essential to keeping the agency’s trains, buses and supporting infrastructure operating smoothly.”

Investors are eagerly anticipating an update from Siyata, regarding its rescheduled press conference, originally slated for this month. Siyata indicated that it expects to provide a formal announcement soon. Market participants are watching closely, as the conference should provide significant insights into Siyata’s growth strategies, recent successes in the U.S. PoC market, and potential new business developments. Stay tuned for updates, as this event could serve as a catalyst for increased investor interest.

Trinity Biotech (NASDAQ: TRIB), a Dublin-based biotechnology company specializing in human diagnostics and diabetes management, announced promising pre-pivotal clinical trial results for its next-generation continuous glucose monitoring (CGM) system. The trial showcased breakthrough performance, including superior signal clarity, improved reliability post-insertion, and a 25-30% accuracy improvement over prior designs. Featuring a modular, eco-friendly design with reusable components, Trinity’s CGM drastically lowers costs compared to leading manufacturers, addressing affordability barriers that have constrained market growth. With a diabetes market projected to exceed $20 billion by 2029, Trinity aims to expand CGM accessibility to millions of underserved individuals while redefining sustainability and affordability in the space. Regulatory approval in the EU and U.S. is targeted for 2025 and 2026, respectively, positioning Trinity as a disruptor in a high-growth market.

IMAC Holdings (NASDAQ:BACK)

IMAC Holdings (NASDAQ: BACK) launched Ignite Proteomics LLC, a subsidiary revolutionizing personalized cancer care through protein-level diagnostics, targeting a $600 million market with potential to disrupt the multi-billion-dollar genomic testing industry. Unlike traditional genomic tests that provide static genetic blueprints, ignites patented multi-protein assay offers real-time insights into tumor activity, enabling more precise selection of advanced therapies like antibody-drug conjugates (ADCs) and immunotherapies. By addressing critical gaps in cancer diagnostics, Ignite reduces costly trial-and-error treatments, enhances patient outcomes, and collaborates with leading cancer centers to expand adoption, positioning IMAC as a key player in the future of personalized oncology.

Transcode Therapeutics (NASDAQ: RNAZ) and Tonix Pharmaceuticals (NASDAQ: TNXP) are two of the most active gainers that didn’t publish an announcement this morning.

Additional 24/7 Market News Siyata disclosure

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (SLXN, SYTA, TRIB, BACK, RNAZ, TNXP)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.